Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204459 · ClinicalTrials.gov registry record
MS-ResearchBiomarkerS
A clinical trial of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting), sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05204459: Recruiting study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting), sponsored by Cedars-Sinai Medical Center.
NCT05204459 is a study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting) that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 1,000 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (72% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05204459, a study of Multiple Sclerosis and Multiple Sclerosis (Relapsing Remitting), is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.
Primary Outcome
To investigate whether combining information from peripheral blood biomarkers, retinal structural, visual function, as well as historical and ongoing longitudinal MRIs (brain, cervical, and/or thoracic spinal cord) can predict quantitative disability progression risk
Conditions Studied
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-11-11 |
| Est. Completion | 2041-11-11 |
What NCT05204459 shows while recruiting
NCT05204459 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (72% higher).
The record links to 10 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT05204459 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05204459 about?
NCT05204459 is a clinical study titled "MS-ResearchBiomarkerS". This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain...
What is the current status of trial NCT05204459?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-11-11. Estimated completion is 2041-11-11.
What conditions does trial NCT05204459 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Neurologic Disorder, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive.
Who is sponsoring clinical trial NCT05204459?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05204459 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05204459's enrollment target sits among peer trials
1,000 26th of 315 higher than 287 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI